New cancer drug trial targets advanced tumors with genetic weakness
NCT ID NCT07446855
Summary
This early-stage trial is testing a new oral drug called AZD4956, both alone and combined with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapies. The study aims to find safe doses and see if the drug can help control cancer growth in tumors with specific genetic repair defects. It will enroll about 180 participants with various advanced cancers including prostate, ovarian, breast, and pancreatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.